Repligen Corp. Q1 2025: Revenue, Notes, and Risk Factors
Ticker: RGEN · Form: 10-Q · Filed: Apr 29, 2025 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 10-Q |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, financials, risk-factors, debt
TL;DR
RGEN Q1 2025: Revenue up, but watch out for European and customer concentration risks.
AI Summary
Repligen Corp. reported its first quarter 2025 results, ending March 31, 2025. The company's financial performance includes details on sales revenue and royalty income. Key financial instruments mentioned are the 0.375% Convertible Senior Notes due 2024, which were subject to an exchange transaction as of December 31, 2023. The filing also highlights risks related to geographic concentration in Europe and customer concentration.
Why It Matters
This filing provides insight into Repligen's financial health and operational risks for the first quarter of 2025, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: medium — The filing indicates risks related to geographic concentration in Europe and customer concentration, which could impact future revenue streams.
Key Numbers
- 2025-03-31 — Reporting Period End Date (First quarter of fiscal year 2025)
- 2025-04-29 — Filing Date (Date the 10-Q was submitted to the SEC)
- 0.375% — Convertible Senior Notes Interest Rate (Interest rate on notes due 2024)
Key Players & Entities
- REPLIGEN CORP (company) — Filer
- 0.375% Convertible Senior Notes Due 2024 (dollar_amount) — Financial Instrument
- Europe (company) — Geographic Concentration Risk
- 41 SEYON STREET (company) — Business Address
- WALTHAM (company) — Business Address City
FAQ
What was Repligen Corp's sales revenue for the first quarter of 2025?
The filing indicates 'us-gaap:SalesRevenueNetMember' for the period 2025-01-01 to 2025-03-31, but the specific dollar amount is not provided in this snippet.
What is the nature of the 'Exchange Transaction' mentioned?
The filing mentions an 'Exchange Transaction' related to the '0.375% Convertible Senior Notes Due 2024' as of December 31, 2023, but details of the transaction are not specified in this snippet.
What are the primary risks highlighted in the filing regarding geographic concentration?
The filing specifically mentions 'us-gaap:GeographicConcentrationRiskMember' related to 'srt:EuropeMember' for the period 2025-01-01 to 2025-03-31.
Does Repligen Corp. have significant customer concentration risk?
Yes, the filing notes 'us-gaap:CustomerConcentrationRiskMember' with 'srt:MinimumMember' for sales revenue during the period 2024-01-01 to 2024-03-31.
What is the company's fiscal year end?
Repligen Corp.'s fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 29, 2025 regarding REPLIGEN CORP (RGEN).